Reckitt Benckiser Group (OTCMKTS:RBGLY) Upgraded to “Strong-Buy” by UBS Group

UBS Group upgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY) to a strong-buy rating in a research note released on Wednesday morning, Zacks.com reports.

Separately, JPMorgan Chase & Co. lowered Reckitt Benckiser Group from an overweight rating to a neutral rating in a research report on Thursday, August 29th. One analyst has rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Reckitt Benckiser Group presently has an average rating of Hold and an average price target of $7,400.00.

Reckitt Benckiser Group Trading Down 1.1 %

Reckitt Benckiser Group stock opened at $12.24 on Wednesday. Reckitt Benckiser Group has a 1-year low of $10.24 and a 1-year high of $15.03. The firm has a 50-day moving average of $11.37 and a 200-day moving average of $11.35.

Reckitt Benckiser Group Cuts Dividend

The company also recently declared a dividend, which will be paid on Monday, September 23rd. Investors of record on Monday, August 5th will be given a dividend of $0.1915 per share. The ex-dividend date of this dividend is Monday, August 5th.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.